An accurate evaluation of
liver fibrosis is clinically important in chronic
liver diseases. Mac-2
binding protein glycosylation isomer (M2BPGi) is a novel
serum marker for
liver fibrosis. In this
review, we discuss the
role of M2BPGi in diagnosing
liver fibrosis in
chronic hepatitis B and C,
chronic hepatitis C after
sustained virologic response (SVR), and
nonalcoholic fatty liver disease (
NAFLD). M2BPGi predicts not only
liver fibrosis but also the
hepatocellular carcinoma (HCC) development and
prognosis in
patients with
chronic hepatitis B and C,
chronic hepatitis C after SVR,
NAFLD, and other chronic
liver diseases. M2BPGi can also be used to evaluate
liver function and
prognosis in
patients with
cirrhosis. M2BPGi levels vary depending on the
etiology and the presence or absence of
treatment. Therefore, the threshold of M2BPGi for diagnosing
liver fibrosis and predicting HCC development has to be adjusted according to the background and
treatment status.